Inhaled corticosteroids use is common in bronchiectasis, even among patients who don’t meet guideline criteria for ICS use.

A new phase 3 trial shows that DPP-1 inhibition with brensocatib reduces exacerbations and slows lung function decline in ...

Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis, published ...

There was no evidence of either intra- or extra-axial blood or unilateral findings in any of the abnormal head CTs. No patients with a GCS >4 had an abnormal CT at any time. Those patients who ...

The clinical trial findings are important, as there are currently no FDA-approved medications for bronchiectasis, a chronic condition with persistent lung airway inflammation and infection.

Treatment with brensocatib also increased time to the first exacerbation and the proportion of patients remaining ...

In bronchiectasis, neutrophilic inflammation ... No confidentiality agreements were made that precluded the publication of trial findings. The trial was conducted in accordance with the principles ...